Stampfer MJ, Malinow R, Willett WC, et al. A prospective study of plasma
homocysteine and risk of myocardial infarction in US physicians. JAMA
1992;268:877–81.
Bostom AG, Silbershatz H, Rosenberg IH, et al. Nonfasting plasma total
homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham
men and women. Arch Intern Med 1999;159:1077–80.
Folsom AR, Nieto J, McGovern PG, et al. Prospective study of coronary heart
disease incidence in relation to fasting total homocysteine, related genetic polymorphisms,
and B vitamins. Circulation 1998;98:204–10.
Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine
and increased risks of cardiovascular disease. Arch Intern Med
2000;160:422–34.
Meleady R, Graham I. Plasma homocysteine as a cardiovascular risk factor:
causal, consequential, or of no consequence? Nutr Rev 1999;57:299–305
[review].
Williams JE, Paton CC, Siegler IC, et al. Anger proneness predicts coronary
heart disease risk: prospective analysis from the atherosclerosis risk in communities (ARIC)
study. Circulation 2000;101:2034–9.
Kawachi I, Sparrow D, Spiro A 3rd, et al. A prospective study of anger and
coronary heart disease. The Normative Aging Study. Circulation
1996;94:2090–5.
Stoney CM, Engebretson TO. Plasma homocysteine concentrations are positively
associated with hostility and anger. Life Sci 2000;66:2267–75.
Perry IJ, Refsum H, Morris RW, et al. Prospective study of serum total
homocysteine concentration and risk of stroke in middle-aged British men. Lancet
1995;346:1395–8.
Langman LJ, Ray JG, Evrovski J, et al. Hyperhomocyst(e)inemia and the
increased risk of venous thromboembolism: more evidence from a case-control study. Arch
Intern Med 2000;160:961–4.
Cattaneo M, Vecchi M, Zighetti ML, et al. High prevalence of
hyperhomocysteinemia in patients with inflammatory bowel disease: a pathogenic link with
thromboembolic complications? Thromb Haemost 1998;80:542–5.
Clarke R, Smith D, Jobst KA, et al. Folate, vitamin B12, and serum total
homocysteine levels in confirmed Alzheimer disease. Arch Neruol
1998;55:1449–55.
Hoogeveen EK, Kostense PJ, Jakobs C, et al. Hyperhomocysteinemia increases
risk of death, especially in type 2 diabetes : 5-year follow-up of the Hoorn Study.
Circulation 2000;101:1506–11.
Sutterlin M, Bussen S, Ruppert D, Steck T. Serum levels of folate and
cobalamin in women with recurrent spontaneous abortion. Hum Reprod
1997;12:2292–6.
Wouters MG, Boers GH, Blom HJ, et al. Hyperhomocysteinemia: a risk factor in
women with unexplained recurrent early pregnancy loss. Fertil Steril
1993;60:820–5.
Steegers-Theunissen RP, Boers GH, Blom HJ, et al. Hyperhomocysteinaemia and
recurrent spontaneous abortion or abruptio placentae. Lancet 1992;339:1122–3
[letter].
Quere I, Bellet H, Hoffet M, et al. A woman with five consecutive fetal
deaths: case report and retrospective analysis of hyperhomocysteinemia prevalence in 100
consecutive women with recurrent miscarriages. Fertil Steril
1998;69:152–4.
Nelen WL, Blom HJ, Steegers EA, et al. Homocysteine and folate levels as risk
factors for recurrent early pregnancy loss. Obstet Gynecol 2000;95:519–24.
de Vries JI, Dekker GA, Huijgens PC, et al. Hyperhomocysteinaemia and protein
S deficiency in complicated pregnancies. Br J Obstet Gynaecol
1997;104:1248–54.
Goddijn-Wessel TA, Wouters MG, van de Molen EF, et al. Hyperhomocysteinemia: a
risk factor for placental abruption or infarction. Eur J Obstet Gynecol Reprod Biol
1996;66:23–9.
Leeda M, Riyazi N, de Vries JI, et al. Effects of folic acid and vitamin B6
supplementation on women with hyperhomocysteinemia and a history of preeclampsia or fetal
growth restriction. Am J Obstet Gynecol 1998;179:135–9.
Dekker GA, de Vries JI, Doelitzsch PM, et al. Underlying disorders associated
with severe early-onset preeclampsia. Am J Obstet Gynecol 1995;173:1042–8.
Rajkovic A, Catalano PM, Malinow MR. Elevated homocyst(e)ine levels with
preeclampsia. Obstet Gynecol 1997;90:168–71.
Catargi B, Parrot-Roulaud F, Cochet C, et al. Homocysteine, hypothyroidism,
and effect of thyroid hormone replacement. Thyroid 1999;9:1163–6.
Boers GHJ, Smals AGH, Trijbels FJM, et al. Heterozygosity for homocystinuria
in premature peripheral and cerebral occlusive arterial disease. N Engl J Med
1985;313:709–15.
Broekmans WM, Klopping-Ketelaars IA, Schuurman CR, et al. Fruits and
vegetables increase plasma carotenoids and vitamins and decrease homocysteine in humans. J
Nutr 2000;130:1578–83.
Jang Y, Lee JH, Kim OY, et al. Consumption of whole grain and legume powder
reduces insulin demand, lipid peroxidation, and plasma homocysteine concentrations in patients
with coronary artery disease: randomized controlled clinical trial. Arterioscler Thromb
Vasc Biol 2001;21:2065–71.
Nygård O, Refsum H, Ueland PM, Vollset SE. Major lifestyle determinants
of plasma total homocysteine distribution: the Hordaland Homocysteine Study. Am J Clin
Nutr 1998;67:263–70.
Stolzenberg-Solomon RZ, Miller ER 3rd, Maguire MG, et al. Association of
dietary protein intake and coffee consumption with serum homocysteine concentrations in an
older population. Am J Clin Nutr 1999;69:467–75.
Nieto FJ, Comstock GW, Chambless LE, Malinow RM. Coffee consumption and plasma
homocyst(e)ine: results from the Atherosclerosis Risk in Communities Study. Am J Clin
Nutr 1997;66:1475–85 [letter].
DeRose DJ, Charles-Marcel ZL, Jamison JM, et al. Vegan diet-based lifestyle
program rapidly lowers homocysteine levels. Prev Med 2000;30:225–33.
Glueck CJ, Shaw P, Land JE, et al. Evidence that homocysteine is an
independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol
1995;75:132–6.
Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ. Vitamin B12, vitamin B6,
and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr
1993;57:47–53.
Ubbink JB, Vermaak WJH, ven der Merwe A, et al. Vitamin requirements for the
treatment of hyperhomocysteinemia in humans. J Nutr 1994;124:1927–33.
Dierkes J, Kroesen M, Pietrzik K. Folic acid and vitamin B6 supplementation
and plasma homocysteine concentrations in healthy young women. Int J Vitam Nutr Res
1998;68:98–103.
Stein JH, McBride PE. Hyperhomocysteinemia and atherosclerotic vascular
disease: pathophysiology, screening, and treatment. Arch Intern Med
1998;158:1301–6.
McGregor D, Shand B, Lynn K. A controlled trial of the effect of folate
supplements on homocysteine, lipids and hemorheology in end-stage renal disease.
Nephron 2000;85:215–20.
Food standards: amendment of standards of identity for enriched grain products
to require addition of folic acid. Fed Regist 1996;61:8781–97.
Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification
on plasma folate and total homocysteine concentrations. N Engl J Med
1999;340:1449–54.
Malinow MR, Duell PB, Hess DL, et al. Reduction of plasma homocyst(e)ine
levels by breakfast cereal fortified with folic acid in patients with coronary heart disease.
N Engl J Med 1998;338:1009–15.
Wilcken DEL, Wilcken B, Dudman NPB, Tyrrell PA. Homocystinuria—the
effects of betaine in the treatment of patients not responsive to pyridoxine. N Engl J
Med 1983;309:448–53.
Jancin B. Amino acid defect causes 20% of atherosclerosis in CHD. Family
Pract News 1994;Oct 15:7.
Garg R, Malinow M, Pettinger M, et al. Niacin treatment increases plasma
homocyst(e)ine levels. Am Heart J 1999;138:1082–7.
Brown WV. Niacin for lipid disorders. Postgrad Med
1995;98:185–93 [review].
Guyton JR. Effect of niacin on atherosclerotic cardiovascular disease. Am
J Cardiol 1998;82(12A):18U–23U [review].